Tvaster Genkalp Raises USD 1.25 Mn Funding to Scale Early Liver Cancer Detection
Ideaspring Capital is leading a USD 1.25 million Pre-Series A investment round for Tvaster Genkalp, a cutting-edge molecular diagnostics firm.
Prominent liver transplant surgeon Prof. Mohamed Rela and Invigo Softwares are current investors.
The new funding will be used to expedite the development and commercialization of Episcreen Liver, a state-of-the-art liquid biopsy test based on methylation for the early diagnosis of liver cancer.
“The funding will accelerate nationwide deployment of Episcreen™ Liver, offering a non-invasive, highly accurate diagnostic alternative for Hepatocellular Carcinoma (HCC), the most common form of liver cancer,” said Dr. Srikar Raman, co-founder of Tvaster Genkalp. The test’s 90% sensitivity greatly increases the likelihood of early identification and survival when compared to the current standard, Alpha-Fetoprotein (AFP), which has a 50% sensitivity.
Tvaster Genkalp, which was founded in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, specializes in molecular diagnostics and precision oncology through the use of cutting-edge epigenetic technology. The business intends to add assays for juvenile hepatoblastoma and cholangiocarcinoma to its oncology diagnostics portfolio.
“We believe that Tvaster’s method has enormous potential for both initial diagnosis and recurrence monitoring in patients receiving therapy. Using more than 600 patient samples, their liquid biopsy test, Episcreen Liver, was created and validated, and it has a 90% sensitivity and specificity rate for identifying hepatocellular carcinoma (HCC). According to Ideaspring Capital’s Naganand Doraiswany, MD, “early detection can greatly increase survival rates and guarantee patients receive curative treatment early on.”
Entvin AI Raises INR 5 Cr from Y Combinator for Growth
The well-known startup incubator Y Combinator has invested INR 5 crore in Entvin AI, a business that specializes in AI solutions.
With an emphasis on mid-to-large pharmaceutical companies globally, the funds will be utilized to expand Entvin’s AI capabilities and increase client acquisition.
Sanskar Jain, Hemant Phalak, and Rishabh Arya, all graduates of IIT Bombay, founded Entvin AI in 2021 with the goal of streamlining the lengthy and intricate FDA drug clearance procedure for life sciences firms. Their AI technology streamlines workflows and drastically cuts down on the time and resources needed for FDA compliance by automating regulatory duties like document generation, compliance verification, and regulatory monitoring.
“We saw a big chance to change how life sciences companies deal with regulations,” stated Sanskar Jain, co-founder and CEO of Entvin AI. By streamlining these processes, our AI agents free up teams to concentrate on strategic goals rather than paperwork.
Entvin’s platform has already saved regulatory teams hundreds of hours, increasing compliance accuracy and lowering risks, thanks to early success in enterprise pilot programs. In order to meet the urgent need for quicker, more effective regulatory procedures, the company intends to increase its AI capabilities and establish itself in the pharmaceutical sector.
Evenflow Raises USD 5 Mn in Series A
As part of a continuing Series A round of USD 5 million, Evenflow, India’s top brand house, has raised further funds from Sunder Ramachandran, Venture Catalysts, and a number of angel investors.
After an unreported bridge deal in October 2024, this transaction brings Evenflow’s total capital raised to around USD 14 million.
Established in 2021, Evenflow oversees a portfolio of brands that includes Frenchware, Xtrim, Yogarise, Rusabl, BabyPro, Trendy Homes, and Cinagro. Through the use of marketplaces and rapid commerce platforms like Amazon, Flipkart, Myntra, and Walmart, these brands have expanded by an astounding 350% and are now available in India, the US, and the MENA area.
The new funding will be used to further scale Evenflow’s brands, increase operational synergies, and boost profitability. The CEO and co-founder of Evenflow, Utsav Agarwal, stated, “As we grow, we are starting to see backend synergies play out, lowering costs per unit and providing pricing flexibility, which is turning our big bets into a profitable engine.”
By 2027, Evenflow wants to have doubled its sales and quadrupled its earnings, with an emphasis on growing its workforce while being profitable.
